The Effect of Diffuse Liver Diseases on the Occurrence of Liver Metastases in Cancer Patients: A Systematic Review and Meta-Analysis

Filippo Monelli 1,2, Giulia Besutti 1,2,*, Olivera Djuric 3,4, Laura Bonvicini 3, Roberto Fari 5, Stefano Bonfatti 5, Guido Ligabue 5, Maria Chiara Bassi 6, Angela Damato 7, Candida Bonelli 7, Carmine Pinto 7, Pierpaolo Pattacini 2 and Paolo Giorgi Rossi 3

Abstract: This systematic review with meta-analysis aimed to assess the effect of diffuse liver diseases (DLD) on the risk of synchronous (S-) or metachronous (M-) liver metastases (LMs) in patients with solid neoplasms. Relevant databases were searched for systematic reviews and cross-sectional or cohort studies published since 1990 comparing the risk of LMs in patients with and without DLD (steatosis, viral hepatitis, cirrhosis, fibrosis) in non-liver solid cancer patients. Outcomes were assessed using the Newcastle-Ottawa Scale. We report the pooled relative risks (RR) for S-LMs and hazard ratios (HR) for M-LMs. Subgroup analyses included DLD, primary site and continent. Nineteen studies were included (n = 37,591 patients), the majority on colorectal cancer. ROB appraisal results were mixed. Patients with DLD had a lower risk of S-LMs (RR 0.50, 95% CI 0.34–0.76), with a higher effect for cirrhosis and a slightly higher risk of M-LMs (HR 1.11, 95% CI, 1.03–1.19), despite a lower risk of M-LMs in patients with vs without viral hepatitis (HR 0.57, 95% CI 0.40–0.82). There may have been a publication bias in favor of studies reporting a lower risk for patients with DLD. DLD are protective against S-LMs and slightly protective against M-LMs for viral hepatitis only.

Keywords: diffuse liver disease; NAFLD; hepatic viral infection; cirrhosis; liver metastasis; colorectal cancer; lung cancer; breast cancer; pancreatic cancer
1. Introduction

In most cases, cancer causes death through the growth of distant metastases in vital organs [1]. Due to its double venous system and complex lymphatic system, the liver is one of the most frequent sites of distant metastases. This is particularly the case for colon cancer, with half of associated metastases in the liver; rectal, breast, pancreatic and lung cancers also frequently metastasize to this organ. Thus, metastatic disease frequently affects prognosis [2], management and therapeutic choices [3].

Diffuse liver diseases include various pathological conditions, some of which, such as liver steatosis, fibrosis and cirrhosis, are very common worldwide. In fact, steatosis is the hallmark of non-alcoholic fatty liver disease (NAFLD), which has an overall global prevalence of 25% [4], while fibrosis and cirrhosis are the final result of several insults to the liver, including chronic viral infections, which reach a prevalence of nearly 5% [5].

Cancer patients have at least the same probability of having diffuse liver disease as the general population, though it is probably higher, given the known association between cancer development and metabolic syndrome, frequently characterized by liver steatosis [6]. Moreover, cancer patients have a higher risk of developing diffuse liver diseases as a consequence of treatment.

In recent years, pathogenetic research and new cancer treatments have focused more on tumor and organ microenvironments than on the cancer cells themselves [7]. Since the microenvironment of the target organ is recognized as a central factor in the process of forming organ metastases, it is reasonable to think that diffuse liver diseases may have an impact on the occurrence of liver metastases. In fact, the ability of metastatic cells to survive and proliferate in the liver is determined by the complex interactions between tumor cells and preexisting tissue cells, including the sinusoidal endothelium, stellate, Kupffer and inflammatory cells [8]. This interplay may be modified by diffuse liver diseases, which influence the liver microenvironment, thereby potentially favoring or hindering the development of hepatic metastases [9,10]. Similarly, chemotherapy-induced liver modifications, although temporary in some cases [11], may also influence the probability of developing liver metastases.

Some studies have analyzed the association between the presence of diffuse liver diseases and liver metastasis occurrence in cancer patients, but the literature on this topic appears to be fragmented and somewhat contradictory.

The aim of this systematic review was to assess the effect of the presence of diffuse liver diseases (steatosis, viral hepatitis, cirrhosis and fibrosis) on the risk of having liver metastasis at diagnosis (synchronous) or developing liver metastases after the diagnosis (metachronous) in patients with solid neoplasms, excluding hepatic primary tumors.

2. Materials and Methods

2.1. Study Eligibility

Systematic reviews and cross-sectional or cohort studies were eligible if they assessed whether the risk and timing of developing liver metastases in patients with solid cancers was different between patients with and those without chronic liver injury. Studies specifically addressing the recurrence of liver metastases after an R0 (i.e., without residual disease) liver resection for metastases of solid neoplasms in patients with and without liver injury at the moment of resection were included. The complete protocol has been registered in the PROSPERO database (ID CRD42019133519).

The diffuse liver diseases considered were liver steatosis, chronic viral hepatitis or chronic hepatitis virus infection, liver cirrhosis and liver fibrosis. The primary tumors considered were all solid tumors except primary liver neoplasms.

The included studies had to have reported a direct comparison between two groups of patients with a solid neoplasm: patients with chronic liver injury (exposed) and patients without chronic liver injury (nonexposed).

Exclusion criteria were hematologic neoplasms, primary liver neoplasms, absence of a comparison between different exposure levels, animal studies, studies on solid malig-
nancies with a follow-up of less than 12 months in cases of lung and pancreatic cancer or 24 months for every other type of tumor. Studies reported only as abstracts or published in languages other than English, German, Spanish, French and Italian were excluded.

2.2. Outcomes and Rationale of the Comparisons

The primary endpoints considered were the presence of liver metastases at diagnosis (synchronous) and the development of liver metastases during follow-up (metachronous). For synchronous metastases, the outcome was computed as prevalence of cases with liver metastases out of the total number of diagnosed cases; for metachronous metastases, the outcomes considered were liver metastasis-free survival (measured as hazard ratio from survival times) and cumulative risk of liver metastases (measured as the proportion after a predefined follow-up or rate using person/time as denominator). Overall survival was considered only for the studies reporting liver metastasis-free survival as well. Finally, the overall cumulative risk of liver metastases (synchronous and metachronous together) was considered for studies in which both types of metastases were explicitly reported for all incident cancers occurring in the same population and in the same time period. Overall survival was considered only to determine whether differences in this outcome between patients with and those without liver disease introduced a bias due to competitive mortality that may have affected the accuracy of liver metastasis-free survival. Instead, the cumulative incidence of synchronous and metachronous metastases was included to determine whether differences between patients with and those without liver disease in the prevalence of synchronous metastases could have been due to a difference in the detection of prevalent metastases. If the presence of a liver disease affected the probability of detecting liver metastases at diagnosis because of the different number, type and accuracy of tests performed in patients with or without liver disease, undetected metastases would occur in follow-up as metachronous metastases. Thus, by comparing the sum of metastases occurring at diagnosis and those in follow-up, we should overcome this possible bias, on the condition that the patients included in the two analyses represent an unselected sample of all incident cancers in the same period.

2.3. Study Search and Selection

A systematic search was conducted in MEDLINE, The Cochrane Library, EMBASE and Scopus, adapting the search strategy (Appendix A) to the requirement of each database including studies from 1990. This date limit was introduced because of the presence of a certain heterogeneity in the definition of “chronic liver injury,” which is more relevant in studies before 1990 [12]. This is particularly important for chronic viral infection, since hepatitis C virus was discovered in 1989 [13] and the first clinical diagnostic tests were developed in 1990 [14].

The last search was conducted in September 2019; the search strategy designed for MEDLINE is reported in the Supplementary Methods section.

One reviewer (FM) screened the search results based on title/abstract; a second reviewer (GB) screened a computer-generated random sample of 25% of the references to identify potential disagreement, resolved by consensus. Then, two reviewers (FM and GB) independently examined eligibility based on the full text of the relevant articles in a two-step procedure: first, removing articles not pertinent to the research question and second, removing articles without a specific analysis of the eligibility criteria and considered outcomes. In cases of disagreement, inclusion was decided by group consensus involving a third reviewer (PGR).

2.4. Data Extraction and Synthesis

Two reviewers (FM and RF) extracted data on study design, country, objective, population (number and characteristics of included patients and controls), how the diagnosis of diffuse liver disease was performed, tumor type, outcomes, inclusion and exclusion criteria, presence, type and length of follow-up and results. Differences between reviewers
were resolved by consensus; when this was not possible, by a third reviewer (GB). These data were collected in a standard data extraction form. Two reviewers (FM and SB) used the Newcastle–Ottawa Scale (NOS) [15] to assess selected studies for the risk of bias by consensus; a third reviewer was called in in cases of disagreement (PGR). In the absence of a universally accepted assessment tool for cross-sectional studies, we chose to modify the NOS to evaluate them by removing non-relevant fields. The original and modified NOS are reported in the Supplementary Material.

2.5. Statistical Analysis

Descriptive analysis was done to summarize the distribution of synchronous and metachronous metastases among exposed and non-exposed patients, as well as to summarize the survival among those studies reporting metachronous metastases to assess whether survival bias could have influenced the results.

Separate meta-analyses were performed for synchronous and metachronous metastases. For synchronous metastases, relative risks (RR) were combined and the pooled RRs, with the 95% CI, were calculated, while for the metachronous metastases, hazard ratios (HR), with 95% CI, were calculated. Both types of point estimates were calculated using the random-effects model described by DerSimonian and Laird [16,17]. When available, adjusted HRs obtained in multivariable analyses were used. Missing HRs and standard errors were imputed using methods for incorporating summary time-to-event data into the meta-analysis, as described by Tierney et al. [18].

Subgroup analyses were performed to investigate the risk of metastases by type of liver injury, primary cancer origin and continent where the study was performed. In all analyses which were not divided by type of liver injury, only one liver injury per study was considered, i.e., if one study reported results for more than one type of liver injury, the classification considered for the primary objective of the study was included in the analysis; in the case of no clear definition of the main objective, the liver disease with the highest number of patients was included.

Forest plots were used to display the RRs or HRs and their corresponding 95% CI. Heterogeneity among the studies was evaluated using I2 statistics. Values of I2 can be interpreted as not important (0–40%), moderate (30–60%), substantial (50–90%) and considerable (75–100%) levels of heterogeneity [19]. The possibility of a publication bias was assessed visually using a funnel plot for asymmetry. Meta-analyses were performed using STATA 13.0, metan command.

3. Results

3.1. Study Selection and Characteristics of the Included Studies

The study selection, according to the PRISMA flow diagram, is reported in Figure 1. For excluded studies, reasons for exclusion are reported in Table S1.

Nineteen studies met the inclusion criteria and were included in synthesis, for a total of 37,591 patients: 6868 exposed and 29,992 non-exposed (Table 1). Among the 19 included studies [20–38], five reported overall survival [23,24,31,33,34]. The majority of the selected studies focused on liver metastases from colorectal cancer, while four focused on other cancers. Analyzing the etiology of liver disease, of the studies on colorectal cancer, three are on liver cirrhosis, four on liver steatosis, eight on hepatic viruses and one on liver fibrosis; two studies include two etiologies, analyzing both steatosis and cirrhosis in one case and hepatic viruses in the other. Of the non-colorectal cancer studies, two are on hepatic viruses, pancreatic cancer and nasopharyngeal carcinoma and two on hepatic steatosis, breast cancer and non-small cell lung cancer. Sixteen studies are on first occurrence of metastasis from primitive cancer and three on metastasis recurrence after R0 liver metastasis resection, two on colorectal cancer metastasis to liver steatosis and two on colorectal cancer metastasis to the liver with chronic hepatic virus infection.
Cancers 2021, 13, x 5 of 17

of metastasis from primitive cancer and three on metastasis recurrence after R0 liver me-
tastasis resection, two on colorectal cancer metastasis to liver steatosis and two on colo-
rectal cancer metastasis to the liver with chronic hepatic virus infection.

Figure 1. PRISMA flow diagram representing records identified through the literature search, screened and included in the synthesis.

| Author/Year | Primary Cancer Site | Diffuse Liver Disease | Study Design | Outcome | Primary/R0 | Hospital/Population-Based | Events/Total | Events/Exposed | Events/Non-Exposed | LD Diagnosis Method | LD Diagnosis Timing | Follow-Up Exposed | Follow-Up Non-Exposed | Age (Years) | Ed | Age (Years) | Non-Exposed |
|-------------|---------------------|-----------------------|--------------|---------|------------|--------------------------|--------------|----------------|-------------------|-------------------|-----------------|----------------|---------------------|-------------|---|-------------|------------|
| Uetsuji 1992 [21] | CRC Cirr Cr-Sec S PR HOS | 40/250 | 0/46 | 40/204 | Bilirubin > 1.5, Albumin < 3.5, Cholinesterase < 3500, GGT > 46, IG retention rate at 15 ′ > 15% | At PR surgery | - | - | - | - |
| Iascone 2005 [22] | CRC Cirrs Cr-Sec S PR HOS | 182/576 | 8/171 | 174/405 | Biopsy | At PR surgery | - | - | - | - |
| Iascone 2005 [22] | CRC Steat Cr-Sec S PR HOS | 179/576 | 5/33 | 174/543 | Biopsy | At PR surgery | - | - | - | - |
| Uetsuji 1992 [21] | CRC Vir Cr-Sec S PR HOS | 40/250 | 4/76 | 36/174 | Blood Test | At PR surgery | - | - | - | - |
| Huo 2018 [28] | CRC Vir Cr-Sec S PR HOS | 364/4033 | 38/244 | 326/3789 | Blood Test | At PR diagnosis | - | - | - | - |
| Iascone 2005 [29] | CRC Vir Cr-Sec S PR HOS | 189/630 | 15/87 | 174/543 | Blood Test Before PR surgery | - | - | - | - |

Figure 1. PRISMA flow diagram representing records identified through the literature search, screened and included in the synthesis.
| Author/Year | Primary Cancer Site | Diffuse Liver Disease | Study Design | Outcome | Primary/R0 | Hospital/Population-Based | Events/Total | Events/Exposed | Events/Non-Exposed | LD Diagnosis Method | LD Diagnosis Timing | Follow-Up Exposed | Follow-Up Non-Exposed | Age (Years) Exposed | Age (Years) Non-Exposed |
|-------------|---------------------|-----------------------|--------------|---------|------------|--------------------------|--------------|----------------|-------------------|------------------|-------------------|----------------|-------------------|----------------|-------------------|
| Uetsuji 1992 [21] | CRC | Cirr | Cr-Sec | S | PR | HOS | 40/250 | 0/46 | 40/204 | Bilirubin > 1.5, Albumin < 3.5, Cholinesterase < 3500, GGT > 46, IG retention rate at 15′ > 15% | At PR surgery | - | - | 57.3 | 62.7 |
| Iascone 2005 [22] | CRC | Cirrs | Cr-Sec | S | PR | HOS | 182/576 | 8/171 | 174/405 | Biopsy | At PR surgery | - | - | 71.2 | 65.8 |
| Uetsuji 1992 [21] | CRC | Steat | Cr-Sec | S | PR | HOS | 179/576 | 5/33 | 174/543 | Biopsy | At PR surgery | - | - | - | - |
| Huo 2018 [28] | CRC | Vir | Cr-Sec | S | PR | HOS | 364/4033 | 38/244 | 326/3789 | Blood Test | Before PR diagnosis | - | - | 57.3 | 62.7 |
| Iascone 2005 [29] | CRC | Vir | Cr-Sec | S | PR | HOS | 189/630 | 15/87 | 174/543 | Blood Test | Before PR surgery | - | - | 69.8 | 65.8 |
| Wang 2012 [32] | CRC | Vir | Cr-Sec | S | PR | HOS | 50/354 | 2/70 | 48/284 | Blood Test | Before PR surgery | - | - | 52.9 | 56.2 |
| Chiou 2014 [20] | CRC | Cirr | Cohort | M | PR | POP | 2529/14865 | 516/2973 | 2013/11892 | NatReg: ICD-9-CM: 571.2, 571.5, 571.6 | Before PR surgery | - | - | 67.6 | 67.6 |
Table 1. Cont.

| Author/Year | Primary Cancer Site | Diffuse Liver Disease | Study Design | Outcome | Primary/R0 | Hospital/Population-Based | Events/Total | Events/Exposed | Events/Non-Exposed | LD Diagnosis Method | LD Diagnosis Timing | Follow-Up Exposed | Follow-Up Non-Exposed | Age (Years) Exposed | Age (Years) Non-Exposed |
|-------------|---------------------|-----------------------|--------------|---------|------------|---------------------------|--------------|---------------|------------------|-------------------|--------------------|-------------------|---------------------|-------------------|---------------------|
| Hamady 2012 [23] | CRC | Steat | Cohort | M | R0 | HOS | 1118/2715 | 437/927 | 681/1788 | Biopsy | At LM resection | 34 | 16% > 75 | 15% > 75 |
| Ramos 2015 [24] | CRC | Steat | Cohort | S/M | R0 | HOS | S:511/943 | S:194/421 | S:317/513 | Biopsy | At LM resection | 47.05 | 62.6 | 62.9 |
| Hayashi 1997 [25] | CRC | Steat | Cohort | S | PR | HOS | 117/839 | 2/121 | 115/718 | Ultrasound | At PR diagnosis | - | - | 58.5 | 61.4 |
| Murono 2013 [26] | CRC | Steat | Cohort | S/M | PR | HOS | S:54/604 | S:2/63 | S:52/541 | CT (HU liver/spleen < 1.1) | Before PR surgery | - | - | 65 | 67.2 |
| Kin Pan Au 2018 [27] | CRC | Vir | Cohort | S | R0 | HOS | 185/304 | 13/21 | 172/283 | Blood Test | Before LM resection | - | - | 61 | 60 |
| Li Destri 2013 [30] | CRC | Vir | Cohort | M | PR | HOS | 44/488 | 1/31 | 43/457 | Blood Test | Before PR diagnosis | 108 | 61 | 66 |
| Qian 2014 [31] | CRC | Vir | Cohort | S/M | PR | HOS | S:133/1413 | S:7/138 | S:126/1275 | Blood Test | Before PR surgery | 72.3 | 58.5 | 59.2 |
| Zeng 2013 [33] | CRC | Vir | Cohort | S/M | PR | HOS | S:211/2868 | S:14/373 | S:197/2495 | Blood Test | - | 65 | 57 | 61 |
| Kondo 2016 [34] | CRC | Fibr | Cohort | M | PR | HOS | 54/953 | 8/77 | 46/876 | NFS > 0.676 | - | 51.2 | 75.3 | 64.9 |
### Table 1. Cont.

| Author/Year | Primary Cancer Site | Diffuse Liver Disease | Study Design | Outcome | Primary/R0 | Hospital/Population-Based | Events/Total | Events/Exposed | Events/Non-Exposed | LD Diagnosis Method | LD Diagnosis Timing | Follow-Up Exposed | Follow-Up Non-Exposed | Age (Years) | Age (Years) |
|-------------|---------------------|-----------------------|--------------|---------|------------|--------------------------|--------------|---------------|-------------------|-------------------|-------------------|------------------|---------------------|--------------|--------------|
| Wu 2017 [35] | Breast | Steat | Cohort | M | PR | HOS | 123/1230 | 27/372 | 96/858 | Ultrasound | At PR diagnosis | 30.7 | 32.4 | 50% > 50 | 35% > 50 |
| Wu 2019 [36] | Lung | Steat | Cohort | M | PR | HOS | 166/1873 | 58/408 | 108/1465 | Ultrasound | At PR diagnosis | 14.5 | - | 67% > 60 | 51% > 60 |
| Wei 2013 [37] | Pancreas | Vir | Cohort | S | PR | HOS | 156/460 | 29/63 | 127/397 | Blood Test | At PR diagnosis | 12 | - | - | - |
| Li 2019 [38] | NPC | Vir/Steat | Cohort | M | PR | HOS | 64/1367 | 13/123 | 51/492 | Blood Test | At PR diagnosis | 27.8 | - | 10% ≥ 60 | 11% ≥ 60 |
| TOT CRC | | | | | | | 32661 | 5872 | 26780 | | | | | | |
| TOT NON-CRC | | | | | | | 4930 | 966 | 3212 | | | | | | |
| TOT | | | | | | | 37591 | 6868 | 29992 | | | | | | |

Synopsis of the included studies subdivided by type of diffuse liver disease and reporting primary cancer site, considered outcomes, number of patients included and number of patients in exposed and non-exposed groups. Primitive/R0 refers to patients’ condition at the moment of inclusion (at diagnosis of primitive cancer or after R0 liver metastasis resection). Follow-up is expressed in months. Cirr, Cirrhosis; Steat, Steatosis; Vir, Virus; Fibr, Fibrosis; Cr-Sec, Cross-Sectional; HOS, Hospital-based study; Pop, Population-based study; PR, Primary; CRC, colorectal cancer; NPC, nasopharyngeal cancer; M, metachronous liver metastases; S, synchronous liver metastases; NatReg, National register; TOT, total number of patients; NFS, NAFLD fibrosis score; LM, liver metastasis, HU, Hounsfield Unit; GGT, Gamma-glutamyltransferase; IG, Indocyanine green; ICD, International Classification of Diseases. ICD-9-CM codes: 571.2, alcoholic cirrhosis of liver; 571.5, cirrhosis of liver without mention of alcohol; 571.6, biliary cirrhosis.
It was possible to extract quantitative information on synchronous liver metastases from 12 studies and quantitative information on metachronous liver metastases from 11 studies; four provided information on both metastasis types, but only two of these were studies on all incident cases (Qian 2014 [31], Zeng 2013 [33]), while the other two included patients after liver metastasis resection. Publication dates ranged from 1992 to 2019, but the time span was much shorter for studies addressing metachronous metastases (2012–2019).

3.2. Risk of Bias

The results of the consensus appraisal according to NOS and modified NOS are presented in Table 2. The scores attributed to the selection domain were generally high, reflecting a correct selection of exposed and non-exposed cohorts and a clear definition of exposure, while some concern for studies evaluating metachronous liver metastases derived from the uncertain absence of metastases at study start. As for the comparability domain, the major concern was the lack of homogeneity between exposed and non-exposed patients in terms of major confounders, this being truer for hospital-based rather than population-based studies. However, among the included studies on metachronous liver metastases, eight presented adjusted analysis (Chiou 2014 [20], Hamady 2012 [23], Murono 2013 [26], Qian 2014 [31], Kondo 2016 [34], Wu 2017 [35], Wu 2019 [36], Li 2019 [38]) one did not use adjustments but included analysis on matched patients (Ramos 2015 [24]) and only two (Zeng 2013 [33] and Li Destri 2013 [30]) did not provide adjusted hazard ratios. Among confounders included into the adjusted analyses, age, sex, T and N staging components were always present, although two studies did not provide clear indications of considered confounders (Qian 2014 [31] and Chiou 2014 [20]). Finally, the low scores of the outcome domain were frequently due to the inadequate assessment of the occurrence of metastases and the duration of follow-up.
### Table 2. Newcastle-Ottawa Scale appraisal of included studies.

| Author/Year | ROB | Selection | Representativeness of EXPOSED Cohort | Selection of Non-EXPOSED Cohort | Ascertainment of Exposure | Outcome of Interest Not Present at Study Start | Comparability | Comparability on the Basis of the Design or Analysis | Outcome | Assessment of Outcome | Follow-Up Long Enough for Outcomes | Adequacy of Follow-Up |
|-------------|-----|-----------|--------------------------------------|---------------------------------|---------------------------|---------------------------------------------|--------------|--------------------------------------------------|---------|---------------------|-------------------------------|----------------------|
| Chiou 2014  | 5/9 | 3/4       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 1/3     | ☼                   | ☼                            | ☼                    |
| Uetsuji 1992| 4/6 | 3/3       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 0/1     | ☼                   | ☼                            | ☼                    |
| Iascone 2005| 4/6 | 3/3       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 0/1     | ☼                   | ☼                            | ☼                    |
| Hamady 2012 | 8/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 2/3     | ☼                   | ☼                            | ☼                    |
| Ramos 2015  | 8/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 2/3     | ☼                   | ☼                            | ☼                    |
| Hayashi 1997| 7/9 | 3/4       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |
| Murono 2013 | 6/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 0/3     | ☼                   | ☼                            | ☼                    |
| Kin Pan Au  | 9/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |
| Huo 2018    | 6/6 | 3/3       | ☼ ☼ ☼                               | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 1/1     | ☼                   | ☼                            | ☼                    |
| Iascone 2005| 4/6 | 3/3       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 1/1     | ☼                   | ☼                            | ☼                    |
| Li Destri 2013| 7/9 | 3/4       | ☼ ☼ ☼                               | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |
| Qian 2014   | 6/9 | 3/4       | ☼ ☼ ☼                               | ☼ ☼                             | 0/2                       | ☼                                          | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |
| Wang 2012   | 4/6 | 2/3       | ☼ ☼                                 | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 1/1     | ☼                   | ☼                            | ☼                    |
| Zeng 2013   | 6/9 | 3/4       | ☼ ☼ ☼                               | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 1/3     | ☼                   | ☼                            | ☼                    |
| Kondo 2016  | 3/9 | 1/4       | ☼                                    | ☼ ☼                             | 0/2                       | ☼                                          | ☼            | ☼                                              | 2/3     | ☼                   | ☼                            | ☼                    |
| Wu 2017     | 8/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |
| Wu 2019     | 7/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 1/2                       | ☼                                          | ☼            | ☼                                              | 2/3     | ☼                   | ☼                            | ☼                    |
| Wei 2013    | 6/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 0/2                       | ☼                                          | ☼            | ☼                                              | 2/3     | ☼                   | ☼                            | ☼                    |
| Li 2019     | 9/9 | 4/4       | ☼ ☼ ☼ ☼                             | ☼ ☼                             | 2/2                       | ☼ ☼                                        | ☼            | ☼                                              | 3/3     | ☼                   | ☼                            | ☼                    |

Appraisal of included guidelines using NOS for cohort and case-control studies and modified NOS for cross-sectional studies. T, primary cancer site; CRC, colorectal cancer; NPC, nasopharyngeal cancer; MET, metachronous liver metastases; SYN, synchronous liver metastases.
3.3. Meta-Analyses

3.3.1. Synchronous Metastases

Meta-analysis of the overall risk of having synchronous metastases in patients with vs without diffuse liver diseases showed lower risk among the former group (RR 0.50; 95% CI 0.34–0.76), with considerable overall heterogeneity (I² 89.4%) (Figure 3). The difference between exposed and non-exposed patients was higher for patients with cirrhosis (RR 0.14; 95% CI 0.07–0.27; I² 0%) than for those with steatosis (RR 0.37; 95% CI 0.15–0.93; I² 80%). Although this result was compatible with random fluctuations, patients with viral hepatitis also had a slightly lower risk of synchronous metastases when compared with patients without viral hepatitis (RR 0.68; 95% CI 0.42–1.10). In this last case, heterogeneity was important (I² 86.9%), with the three largest studies going in the opposite direction (Huo 2018 [28] colorectal cancer; Wei 2013 [37] pancreatic cancer) or showing no effect (Kin Pan Au 2018 [27] colorectal cancer).

When stratified by primary cancer site, the risk of developing synchronous metastases was higher for patients without liver injury if they had colorectal cancer as primary cancer site (RR 1.44; 95% CI 1.06–1.95) (Figure 3). The difference between exposed and non-exposed patients was higher for patients with cirrhosis (RR 0.14; 95% CI 0.07–0.27; I² 0%) than for those with steatosis (RR 0.37; 95% CI 0.15–0.93; I² 80%). Although this result was compatible with random fluctuations, patients with viral hepatitis also had a slightly lower risk of synchronous metastases when compared with patients without viral hepatitis (RR 0.68; 95% CI 0.42–1.10). In this last case, heterogeneity was important (I² 86.9%), with the three largest studies going in the opposite direction (Huo 2018 [28] colorectal cancer; Wei 2013 [37] pancreatic cancer) or showing no effect (Kin Pan Au 2018 [27] colorectal cancer).

| STUDY_ID          | RR (95% CI)      | Weight |
|-------------------|------------------|--------|
| Uetsuji_1992      | 0.05 (0.00, 0.86) | 1.65   |
| Iascone_2005      | 0.15 (0.07, 0.29) | 7.78   |
| Subtotal (I-squared = 0.0%, p = 0.486) | 0.14 (0.07, 0.27) | 9.43   |
| Ramos_2015        | 0.75 (0.66, 0.85) | 10.18  |
| Hayashi_1997      | 0.09 (0.02, 0.35) | 4.46   |
| Murono_2013       | 0.33 (0.08, 1.32) | 4.45   |
| Iascone_2005      | 0.47 (0.21, 1.07) | 7.07   |
| Subtotal (I-squared = 80.0%, p = 0.002) | 0.37 (0.15, 0.93) | 25.16  |
| Kin Pan Au_2018   | 1.02 (0.72, 1.44) | 9.50   |
| Huo_2018          | 1.15 (1.21, 2.26) | 9.64   |
| Iascone_2005      | 0.54 (0.33, 0.87) | 8.91   |
| Qian_2014         | 0.51 (0.24, 1.08) | 7.49   |
| Wang_2012         | 0.17 (0.04, 0.68) | 4.44   |
| Zeng_2013         | 0.48 (0.28, 0.81) | 6.63   |
| Uetsuji_1992      | 0.25 (0.09, 0.69) | 6.13   |
| Wei_2013          | 1.44 (1.06, 1.95) | 6.67   |
| Subtotal (I-squared = 86.9%, p = 0.000) | 0.68 (0.42, 1.10) | 64.40  |
| Overall (I-squared = 88.7%, p = 0.000) | 0.50 (0.34, 0.74) | 100.00 |

Figure 2. Forest plot displaying the RRs and corresponding 95% CI for synchronous metastases in exposed vs non-exposed patients for different diffuse liver diseases. I² is reported as a measure of heterogeneity. Overall RR and I² were calculated after excluding the comparison between patients with and without steatosis for Iascone 2005 [22] since this was the least represented liver disease in the study.

When stratified by primary cancer site, the risk of developing synchronous metastases was higher for patients without liver injury if they had colorectal cancer as primary cancer site (RR 0.44; 95% CI 0.29–0.69; I² 88.5%). Only one study reported results on pancreatic cancer as the primary cancer site (Wei 2013 [37]) and showed a higher risk of synchronous metastases for those with liver injury (RR 1.44; 95% CI 1.06–1.95) (Figure 3).
metachronous metastases (HR 1.11, 95% CI 1.03–1.19), with considerable overall heterogeneity between exposed vs non-exposed patients stratified by cancer sites. I² is reported as a measure of heterogeneity. When stratified by the continent where the study was conducted, pooled risk estimates obtained in the studies conducted in Asia and those outside of Asia were similar to the overall estimate (Figure 4). For synchronous metastases, the range of publication dates was wide, with older and smaller studies reporting stronger protective effects than more recent studies.

Figure 3. Forest plot displaying the RRs and corresponding 95% CI for synchronous metastases in exposed vs non-exposed patients stratified by cancer sites. I² is reported as a measure of heterogeneity. The comparison between patients with and without steatosis for Iascone 2005 [22] was not considered since this was the least represented liver disease in the study.

Figure 4. Forest plot displaying the RRs and corresponding 95% CI for synchronous metastases in exposed vs non-exposed patients stratified by country. I² is reported as a measure of heterogeneity. The comparison between patients with and without steatosis for Iascone 2005 [22] was not considered since this was the least represented liver disease in the study.
3.3.2. Metachronous Metastases

Overall, people with diffuse liver diseases had a slightly higher risk of developing metachronous metastases (HR 1.11, 95% CI 1.03–1.19), with considerable overall heterogeneity (I² 78%) (Figure 5). However, the only result with low heterogeneity and showing a more convincing effect was in the opposite direction, i.e., a lower risk in patients with viral hepatitis vs those without (HR 0.51, 95% CI 0.35–0.75; I² 0%). Pooled results for steatosis showed a slight increase in risk among exposed patients, with high heterogeneity (HR 1.12; 95% CI 1.01–1.25; I² 80.9%) and similar results were obtained for cirrhosis (HR 1.15; 95% CI 1.04–1.28) and fibrosis (HR 2.87; 95% CI 1.17–7.03), although estimated in one study only.

**Figure 5.** Forest plot displaying the HRs and corresponding 95% CI for metachronous metastases in exposed vs non-exposed patients for different diffuse liver diseases. I² is reported as a measure of heterogeneity. Overall RR and I² were calculated after excluding the comparison between patients with and without steatosis for Li 2019 [38] since this was a secondary outcome in the study.

When stratifying by cancer site, results were heterogeneous between groups. Pooled analysis was possible only for colorectal cancer (HR 1.12; 95% CI 1.03–1.21; I² 80.8%), while for other cancer sites the risk of metachronous liver metastases in patients with liver disease was either higher (HR 1.43; 95% CI 1.02–2.01 for lung cancer) or lower (HR 0.55; 95% CI 0.35–0.86 for breast). For nasopharyngeal cancer, the study was underpowered and inconclusive (HR 0.77; 95% CI 0.38–1.58) (Figure 6).
Figure 6. Forest plot displaying the HRs and corresponding 95% CI for metachronous metastases in exposed vs non-exposed patients stratified by cancer site. I² is reported as a measure of heterogeneity. The comparison between patients with and without steatosis for Li 2019 [38] was not considered since this was a secondary outcome in the study.

When stratified by the continent where the study was conducted, pooled risk estimates obtained in the studies conducted in and outside of Asia were similar to the overall estimate, without significant heterogeneity between groups (Figure 7).

Figure 7. Forest plot displaying the HRs and corresponding 95% CI for metachronous metastases in exposed vs non-exposed patients stratified by country. I² is reported as a measure of heterogeneity. The comparison between patients with and without steatosis for Li 2019 [38] is not considered since this was a secondary outcome in the study.
When excluding the two studies which did not provide adjusted HR (Zeng 2013 [33]
and Li Destri 2013 [30]), the overall estimate did not change.

3.3.3. Studies Evaluating Synchronous and Metachronous Liver Metastases in the
Same Population

Two studies permitted an evaluation of the cumulative incidence of both synchronous
and metachronous liver metastases on the same patient groups, with and without viral
hepatitis (Qian 2014 [31] and Zeng 2013 [33]). Both showed lower risk of metastases in
patients with liver disease: in Qian 2014 [31], cumulatively 9.7% vs. 25.5% and in Zeng
2013 [33], 9.0% vs. 19.6% (Figure 8).

Figure 8. Graph representing the percentages of synchronous and metachronous liver metastases
occurring in exposed and non-exposed patients in studies evaluating both types of metastases.

3.3.4. Publication Bias

The funnel plots for both synchronous and metachronous metastases were not symmet-
rically distributed and several studies were outside of the 95% CI (Figure 9), suggesting a
publication bias toward the studies reporting lower risk for patients with diffuse liver disease.

Figure 9. Cont.
3.3.5. Overall Survival in Studies Reporting Liver Disease Free Survival

Five-year overall survival ranged from 39.3% to 79.8% among the exposed patients and from 39.3% to 92.2% among the non-exposed patients. Two studies (Hamady 2012 [23]; Kondo 2016 [34]) reported lower 5-year survival among exposed patients, while three studies (Ramos 2015 [24]; Qian 2014 [31]; Zeng 2013 [33]) reported higher 5-year survival among non-exposed patients. Given the slight differences, with opposite directions, in overall survival among the studies, compatible with random fluctuations, it is unlikely that differences in overall survival could introduce a serious bias in the results of meta-analyses for liver metastasis survival (Table 3).

Table 3. Overall survival in exposed and non-exposed patients.

| Study             | 5-Year Survival Exposed | Median Survival Exposed | 5-Year Survival Non-Exposed | Median Survival Non-Exposed |
|-------------------|-------------------------|-------------------------|-----------------------------|-----------------------------|
| Hamady 2012 [23]  | 39.3%                   | 22 months               | 42.8%                       | 24 months                   |
| Ramos 2015 [24]   | 55.1%                   |                         | 45.2%                       |                             |
| Qian 2014 [31]    | 40.6%                   | 56 months               | 39.3%                       | 49 months                   |
| Zeng 2013 [33]    | 79.8%                   |                         | 92.2%                       |                             |
| Kondo 2016 [34]   |                         |                         |                             |                             |

4. Discussion

The results of this systematic review and meta-analysis show a slight protective effect of diffuse liver diseases on the presence of synchronous liver metastases. Since this protective effect was more apparent for the most severe liver injury (liver cirrhosis), a dose-response relationship can be hypothesized. A slight protective effect was also found for viral hepatitis on metachronous liver metastases, while the presence of other diffuse liver diseases had no effect or resulted in a slight increase in the risk of developing metachronous liver metastases. The results of the included studies were inconsistent. A considerable heterogeneity was found both overall and when stratifying for type of diffuse liver disease and primary cancer site, while no heterogeneity was found when stratifying by the continent where the study was conducted.

Our analyses suggest a strong publication bias, with smaller studies often supporting extreme results particularly in favor of a lower risk of metastases in patients with liver disease. Hospital-based studies may underestimate the risk of metastases in patients with liver disease due to selection bias. In fact, research hospitals can attract more complex cases and complexity could be due to a preexisting condition such as liver disease or to cancer severity. Thus, in hospital-based rather than population-based studies, patients with diffuse liver diseases could be centralized to regional research hospitals at less advanced cancer stages than are patients without liver disease.
The high inconsistency and heterogeneity may partially derive from the design and patient inclusion criteria applied by most of the studies found in the literature. In fact, most studies assessing metachronous metastases did not also evaluate synchronous metastases. By excluding patients with baseline liver metastases, the risk is to look at one part of the picture only. For instance, patients with a diffuse liver disease may undergo a higher number and different types of diagnostic examinations. This may lead to anticipating the diagnosis of a primary tumor, thereby shifting stage at diagnosis towards non-metastatic primary tumor in exposed patients. This early diagnosis may explain the finding of a protective effect of cirrhosis on synchronous but not on metachronous liver metastases. Further, this protective effect is seen in colorectal cancer patients, who may benefit from earlier cancer detection and not in pancreatic cancer patients, seemingly confirming the hypothesis of an early diagnosis. Of course, for colorectal cancer this hypothesis would be unconvincing in the era of screening, when the vast majority of cancers in the general population are diagnosed in early stage, but it is worth noting that the included studies on cirrhosis and synchronous metastases included cancers diagnosed before the implementation of colorectal cancer screening programs.

The issue of potential confounders, such as tumor stage, nodal involvement, location of the primitive cancer (in colorectal cancer), chemotherapy regimen and others, was addressed differently in the included studies. In most studies, the authors chose to perform multivariate analyses to adjust for confounders or analyses on matched subpopulations and only in a few studies were confounders not considered or not clearly defined. Unfortunately, none of the included studies provided the number of events stratified by cancer stage, preventing us from producing stratified estimates. However, the adoption of multivariate analyses in most studies, including adjustment for tumoral stage, should reassure us that no biases were introduced by this potential confounder. Neoadjuvant or adjuvant chemotherapy, on the other hand, was rarely taken into consideration in adjusted analyses. However, the rationale for adjusting for chemotherapy is questionable, since tolerability of chemotherapy could be one of the mechanisms leading to a different occurrence of metastases.

Another concern may derive from the long time period over which the studies were carried out, at least for studies on synchronous metastases. However, differences in results by study period are impossible to distinguish from the effect of the study size. Although the diagnostic methods used for the diffuse liver diseases considered have not varied much during the time interval of our analysis, the included studies adopted different definitions of liver disease even for the same kind of liver injury. Instead, new methods for liver metastasis diagnosis were introduced into clinical practice during the study period. However, this should not affect the results of the metaanalysis, since in every study exposed and non-exposed patients were enrolled during the same time span.

Only two small studies on viral hepatitis allowed a comparison of the cumulative occurrence of metastases from diagnosis to follow-up in an unbiased population of patients (Qian 2014 [31]; Zeng 2013 [33]). This comparison does not suggest that differences in synchronous or metachronous metastases may be due to a differentiated assessment of prevalent metastases in the two groups. In fact, both studies found fewer metastases at diagnosis and during follow-up in patients with than in patients without viral hepatitis. Unfortunately, no study allowed this comparison for steatosis or cirrhosis.

Previous metaanalyses have reported a lower risk of liver metastases in injured livers. However, they focused on only one type of diffuse liver disease (cirrhosis) or on only one type of primary cancer site (colorectal cancer) [39]. Compared with previous metaanalyses, our study pays more attention to the issue of synchronous and metachronous liver metastases, both by conducting clearly separated analyses and by trying to consider them together for the studies that allowed it, since the two phenomena may be communicating vessels.

According to our results, the previously hypothesized mechanisms for a lower risk of liver metastases in injured liver seem to be only partially confirmed, possibly more
for viral hepatitis than for other diffuse liver diseases. These mechanisms include the higher concentration of metalloproteinase inhibitor [40], decreased neovascularization [41] and changes in liver-related immunity [42]. All these modifications can affect the various steps required for the transport, implant and adaptation of cancer cells to another organ [43]. Their combined effect may produce a decrease in the effectiveness of the process of metastatization, which is per se inefficient [44].

This systematic review has some limitations. Firstly, since we excluded papers in Chinese and in Japanese and liver disease prevalence is particularly high in Asia, resulting in particularly extensive literature from these countries, we may have missed some relevant papers. Moreover, we considered collectively studies with different assessments of the diffuse liver disease. Liver steatosis can be diagnosed either by imaging techniques or by pathological examination, while for viral hepatitis, some studies included only active disease and others included any serological signs of present or past infection. Only one study (Li 2019 [38]) stratified for different types of viral infection status, suggesting that inactive or resolved infection but not chronic infection had a protective effect on liver metastasis occurrence. Hence, this inconsistency in exposure definitions is probably one of the main sources of residual heterogeneity.

5. Conclusions

Diffuse liver diseases seem to be protective against synchronous liver metastases. This could be the result of earlier cancer diagnosis due to opportunistic screening in patients treated and followed up for liver diseases.

A slight protective effect was also found on metachronous liver metastases for viral hepatitis, while the presence of other diffuse liver diseases had no effect or resulted in a slight increase in the risk of developing metachronous liver metastases.

To clearly answer the question of whether and which diffuse liver diseases influence the probability of developing liver metastases, future studies should be population-based, including all incident cases from stage II (at least) to IV and they should assess simultaneously, but separately, the prevalence of synchronous metastases and the incidence of metachronous metastases.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/cancers13092246/s1, Table S1: Reasons for exclusion.

Author Contributions: Conceptualization, G.B., F.M. and P.G.R.; methodology, P.G.R.; formal analysis, O.D., L.B. and P.G.R.; investigation, M.C.B., F.M., S.B. and R.F.; resources, M.C.B. and F.M.; data curation, F.M., S.B., R.F.; writing—original draft preparation, G.B., F.M. and P.G.R.; writing—review and editing, A.D., C.B., C.P.; visualization, O.D., L.B. and F.M.; supervision, P.G.R., G.L. and P.P.; project administration, G.B., F.M. and P.G.R. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

Appendix A

MEDLINE search strategy: ("Hepatitis, Alcoholic"[Mesh terms] OR "Fatty Liver"[Mesh terms] OR "Hepatitis, Chronic"[Mesh] OR "Hepatitis, Viral, Human"[Mesh terms] OR "Liver Cirrhosis, Alcoholic"[Mesh terms] OR "Liver Cirrhosis, Biliary"[Mesh terms] OR “Liver Disease”[title] OR “fatty liver”[title] OR Steatohepatitis[tile] OR Steatosis[tile] OR Steatoses[tile] OR "Steatotic Liver”[title] OR “nonalcoholic fatty liver disease”[title] OR “non-alcoholic fatty liver disease”[title] OR NAFLD[tile] OR "liver fibrosis”[title] OR “chronic hepatitis”[title] OR cirrhosis[tile]) AND (“Neoplasm Metastasis”[Mesh] OR “Neoplasm Recurrence, Local”[Mesh] OR liver metastasis[tile] OR liver metastases[tile]}
OR metastatic liver[title] OR “Liver Neoplasms/secondary”[Mesh] OR recurrence[title] OR “Cancer Prognosis”[Title]); Filters: English, French, German, Italian, from 1990 to 2019.

References

1. Helling, T.S.; Martin, M. Cause of death from liver metastases in colorectal cancer. Ann. Surg. Oncol. 2014, 21, 501–506. [CrossRef]
2. Zaorsky, N.G.; Churilla, T.M.; Egleston, B.L.; Fisher, S.G.; Ridge, J.A.; Horwitz, E.M.; Meyer, J.E. Causes of death among cancer patients. Ann. Oncol. 2017, 28, 400–407. [CrossRef]
3. Stewart, C.L.; Warner, S.; Ito, K.; Raoof, M.; Wu, G.X.; Kessler, J.; Kim, J.Y.; Fong, Y. Cytoreduction for colorectal metastases: Liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure? Curr. Probl. Surg. 2018, 55, 330–379. [CrossRef]
4. Estes, C.; Razavi, H.; Loomba, R.; Younossi, Z.; Sanyal, A.J. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology 2018, 67, 123–133. [CrossRef] [PubMed]
5. Razavi, H. Global Epidemiology of Viral Hepatitis. Gastroenterol. Clin. N. Am. 2020, 49, 179–189. [CrossRef]
6. Uzunlu, M.; Telci Calikili, O.; Oguz, A. Association between Metabolic Syndrome and Cancer. Ann. Nutr. Metab. 2016, 68, 173–179. [CrossRef] [PubMed]
7. Langley, R.R.; Falder, I.J. The seed and soil hypothesis revisited—the role of tumor-stroma interactions in metastasis to different organs. Int. J. Cancer. 2011, 128, 2527–2535. [CrossRef]
8. Brodt, P. Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches. Clin. Cancer Res. 2016, 22, 5971–5982. [CrossRef] [PubMed]
9. Milette, S.; Sicklick, J.K.; Lowy, A.M.; Brodt, P. Molecular Pathways: Targeting the Microenvironment of Liver Metastases. Clin. Cancer Res. 2017, 23, 6390–6399. [CrossRef]
10. Masaki, S.; Hashimoto, Y.; Kunisho, S.; Kimoto, A.; Kitadai, Y. Fatty change of the liver microenvironment influences the metastatic potential of colorectal cancer. Int. J. Exp. Pathol. 2020, 101, 162–170. [CrossRef] [PubMed]
11. Vigano, L.; De Rosa, G.; Tosco, C.; Andres, A.; Ferrero, A.; Roth, A.; Sperti, E.; Majno, P.; Rubbia-Brandt, L. Reversibility of chemotherapy-related liver injury. J. Hepatol. 2017, 67, 84–91. [CrossRef] [PubMed]
12. Lonardo, A.; Leoni, S.; Alswat, K.A.; Fould, Y. History of Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2020, 21, 5888. [CrossRef] [PubMed]
13. Kuo, G.; Choo, Q.L.; Alter, M.J.; Stevens, C.E.; et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989, 244, 362–364. [CrossRef]
14. Aach, R.D.; Stevens, C.E.; Hollinger, F.B.; Mosley, J.W.; Peterson, D.A.; Taylor, P.E.; Barbosa, L.H.; Nemo, G.J. Hepatitis C virus infection in post-transfusion hepatitis. An analysis with first- and second-generation assays. N. Engl. J. Med. 1991, 325, 1325–1329. [CrossRef]
15. Wells, G.; Shea, B.; O’Connell, D.L.; Peterson, J.; Welch, L.; Losos, M.; Sugwale, P.; Ga, S.W.; Zello, G.; Petersen, J. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses; Ottawa Health Research Institute: Ottawa, ON, Canada, 2014; Available online: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed on 6 May 2021).
16. DerSimonian, R.; Laird, N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7, 177–188. [CrossRef]
17. Harris, R.J.T.; Deeks, J.J.; Altman, D.G.; Bradburn, M.J.; Harbord, R.M.; Sterne, J.A.C. Metan: Fixed- and Random-Effects Meta-Analysis. Stata J. 2008, 8, 3–28. [CrossRef]
18. Tierney, J.F.; Stewart, L.A.; Ghersi, D.; Burdett, S.; Sydes, M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8, 16. [CrossRef]
19. Higgins, J.P.T.; Thomas, J.; Chandler, J.; Cumpston, M.; Li, T.; Page, M.J.; Welch, V.A. (Eds.) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2; Updated February 2020; Cochrane, 2021; Available online: www.training.cochrane.org/handbook (accessed on 15 March 2021).
20. Chiou, W.Y.; Chang, C.M.; Tseng, K.C.; Hung, S.K.; Lin, H.Y.; Chen, Y.C.; Su, Y.C.; Tseng, C.W.; Tsai, S.J.; Lee, M.S.; et al. Effect of liver cirrhosis on metastasis in colorectal cancer patients: A nationwide population-based cohort study. Jpn. J. Clin. Oncol. 2015, 45, 160–168. [CrossRef]
21. Utexui, S.; Yamamura, M.; Yamamichi, K.; Okuda, Y.; Takada, H.; Hioki, K. Absence of colorectal cancer metastasis to the cirrhotic liver. Am. J. Surg. 1992, 164, 193–196. [CrossRef]
22. Iascone, C.; Ruperto, M.; Barillari, P. Metastasi epatiche sincrone da carcinoma colo-rettale in pazienti con cirrosi epatica o steatosi [Occurrence of synchronous colorectal cancer metastasis in the cirrhotic or fatty liver]. Minerva Chir. 2005, 60, 185–190. (In Italian)
23. Hamady, Z.Z.; Rees, M.; Welsh, F.K.; Tooogood, G.J.; Prasad, K.R.; John, T.K.; Lodge, J.P. Fatty liver disease as a predictor of local recurrence following resection of colorectal liver metastases. Br. J. Surg. 2013, 100, 820–826. [CrossRef]
24. Ramos, E.; Torras, J.; Lladó, L.; Rafecas, A.; Serrano, T.; Lopez-Gordo, S.; Busquets, J.; Fabregat, J. The influence of steatosis on the short- and long-term results of resection of liver metastases from colorectal carcinoma. HPB 2016, 18, 389–396. [CrossRef]
25. Hayashi, S.; Masuda, H.; Shigematsu, M. Liver metastasis rare in colorectal cancer patients with fatty liver. Hepatogastroenterology 1997, 44, 1069–1075.
26. Murono, K.; Kitayama, J.; Tsuno, N.H.; Nozawa, H.; Kawai, K.; Sunami, E.; Akahane, M.; Watanabe, T. Hepatic steatosis is associated with lower incidence of liver metastasis from colorectal cancer. *Int. J. Colorectal. Dis.* **2013**, *28*, 1065–1072. [CrossRef] [PubMed]

27. Au, K.P.; Chok, K.S.H.; Chan, A.C.Y.; Dai, W.C.; Cheung, T.T.; Lo, C.M. Impact of Hepatitis B Carrier Status on the Outcomes of Surgical Treatment of Colorectal Liver Metastases. *World J. Surg.* **2018**, *42*, 2642–2650. [CrossRef]

28. Huo, T.; Cao, J.; Tian, Y.; Shi, X.; Wu, L.; Zhang, M.; Wong, L.L.; Zhao, L. Effect of Concomitant Positive Hepatitis B Surface Antigen on the Risk of Liver Metastasis: A Retrospective Clinical Study of 4033 Consecutive Cases of Newly Diagnosed Colorectal Cancer. *Clin. Infect. Dis.* **2018**, *66*, 1948–1952. [CrossRef] [PubMed]

29. Iascone, C.; Ruperto, M.; Barillari, P. Metastasi epatiche da carcinoma colo-rettale in pazienti con infezione da epatite B o C [Colorectal carcinoma metastasis in patients infected with hepatitis B or C virus]. *Minerva Chir.* **2005**, *60*, 77–81. (In Italian) [PubMed]

30. Li Destri, G.; Castaing, M.; Ferlito, F.; Minutolo, V.; Di Cataldo, A.; Puleo, S. Rare hepatic metastases of colorectal cancer in livers with symptomatic HBV and HCV hepatitis. *Ann. Ital. Chir.* **2013**, *84*, 323–327.

31. Qian, H.G.; Hao, C.Y. Hepatitis B virus infection is an independent factor influencing the occurrence of liver metastasis in colorectal cancer: A retrospective analysis of 1413 cases. *Hepatogastroenterology* **2014**, *61*, 1908–1914.

32. Wang, F.S.; Shao, Z.G.; Zhang, J.L.; Liu, Y.F. Colorectal liver metastases rarely occur in patients with chronic hepatitis virus infection. *Hepatogastroenterology* **2012**, *59*, 1390–1392. [CrossRef]

33. Zeng, Y.; He, X.W.; He, X.S.; Wu, X.J.; Ma, J.P.; Wang, J.P.; Lan, P. Chronic hepatic viral infection could be a protective factor for colorectal cancer liver metastases: Analysis in a single institute. *Hepatogastroenterology* **2013**, *60*, 37–41. [CrossRef] [PubMed]

34. Kondo, T.; Okabayashi, K.; Hasogawa, H.; Tsuruta, M.; Shigeta, K.; Kitagawa, Y. The impact of hepatic fibrosis on the incidence of liver metastasis from colorectal cancer. *Br. J. Cancer* **2016**, *115*, 34–39. [CrossRef] [PubMed]

35. Wu, W.; Chen, J.; Ye, W.; Li, X.; Zhang, J. Fatty liver decreases the risk of liver metastasis in patients with breast cancer: A two-center cohort study. *Breast Cancer Res. Treat.* **2017**, *166*, 289–297. [CrossRef]

36. Wu, W.; Liao, H.; Ye, W.; Li, X.; Zhang, J.; Bu, J. Fatty liver is a risk factor for liver metastasis in Chinese patients with non-small cell lung cancer. *PeerJ* **2019**, *7*, e6612. [CrossRef]

37. Wei, X.L.; Qu, M.Z.; Chen, W.W.; Jin, Y.; Ren, C.; Wang, F.; Luo, H.Y.; Wang, Z.Q.; Zhang, D.S.; Wang, F.H.; et al. The status of HBV infection influences metastatic pattern and survival in Chinese patients with pancreatic cancer. *J. Transl. Med.* **2013**, *11*, 249. [CrossRef]

38. Li, X.; Wu, W.; Chen, J.; Ye, W.; Zhang, J.; Wei, T. Effect of hepatitis B virus infection status on liver metastasis of nasopharyngeal carcinoma: A cohort study. *Transl. Cancer Res.* **2019**, *8*, 262–272. [CrossRef]

39. Cai, B.; Liao, K.; Song, X.Q.; Wei, W.Y.; Zhang, Y.; Zheng, P. Patients with chronically diseased livers have lower incidence of colorectal liver metastases: A meta-analysis. *PLoS ONE* **2014**, *9*, e108618. [CrossRef]

40. Barsky, S.H.; Gopalakrishna, R. High metalloproteinase inhibitor content of human cirrhosis and its possible conference of metastasis resistance. *J. Natl. Cancer Inst.* **1988**, *80*, 102–108. [CrossRef] [PubMed]

41. Karube, H.; Masuda, H.; Hayashi, S.; Ishii, Y.; Nemo, N. Fatty liver suppressed the angiogenesis in liver metastatic lesions. *Hepatogastroenterology* **2000**, *47*, 1541–1545.

42. Okuno, K.; Hirai, N.; Lee, Y.S.; Kawai, I.; Shigeoka, H.; Yasutomi, M. Involvement of liver-associated immunity in hepatic metastasis formation. *J. Surg. Res.* **1998**, *75*, 148–152. [CrossRef]

43. Mareel, M.; Leroy, A. Clinical, cellular, and molecular aspects of cancer invasion. *Physiol. Rev.* **2003**, *83*, 337–376. [CrossRef] [PubMed]

44. Chambers, A.F.; Groom, A.C.; MacDonald, I.C. Dissemination and growth of cancer cells in metastatic sites. *Nat. Rev. Cancer* **2002**, *2*, 563–572. [CrossRef] [PubMed]